Victrex’s Buy Rating Reaffirmed at Deutsche Bank (VCT)
Victrex (LON:VCT)‘s stock had its “buy” rating reiterated by analysts at Deutsche Bank in a research report issued to clients and investors on Wednesday, Analyst Ratings News reports. They currently have a GBX 1,825 ($29.28) price target on the stock. Deutsche Bank’s target price suggests a potential upside of 17.82% from the company’s current price.
VCT has been the subject of a number of other recent research reports. Analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Victrex in a research note to investors on Wednesday. They now have a GBX 1,550 ($24.87) price target on the stock. Separately, analysts at Bank of America Corp. reiterated an “underperform” rating on shares of Victrex in a research note to investors on Wednesday. They now have a GBX 1,400 ($22.46) price target on the stock. Finally, analysts at Nplus1 Brewin reiterated a “hold” rating on shares of Victrex in a research note to investors on Tuesday. They now have a GBX 1,645 ($26.39) price target on the stock. Three analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company’s stock. Victrex has a consensus rating of “Hold” and an average target price of GBX 1,661.54 ($26.66).
Shares of Victrex (LON:VCT) traded up 0.19% on Wednesday, hitting GBX 1552.00. The stock had a trading volume of 80,973 shares. Victrex has a 52-week low of GBX 1366.00 and a 52-week high of GBX 1791.00. The stock has a 50-day moving average of GBX 1593. and a 200-day moving average of GBX 1609.. The company’s market cap is £1.307 billion.
Victrex plc is engaged in the manufacturing and selling of high performance polymers. The Company’s business is organized as two business units: Victrex Polymer Solutions (LON:VCT) and Invibio Biomaterial Solutions (Invibio).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.